BAP1 adenovirus

The BAP1 (BRCA1-associated protein 1) gene is a tumor suppressor gene located on chromosome 3p21.1. It encodes a nuclear ubiquitin carboxyl-terminal hydrolase that plays a key role in regulating cellular processes such as DNA damage repair, cell cycle regulation, and chromatin remodeling. BAP1 acts as a deubiquitinating enzyme that regulates the activity of key proteins involved in proliferation and apoptosis. Germline mutations in BAP1 are associated with an increased risk of developing a variety of cancers, including mesothelioma, uveal melanoma, renal cell carcinoma, and other malignancies, a condition known as the BAP1 tumor predisposition syndrome. Somatic mutations or loss of BAP1 expression are also common in sporadic cancers. Due to its involvement in key signaling pathways, BAP1 has emerged as a promising therapeutic target for cancer treatment.

The BAP1 adenovirus is a recombinant adenoviral vector designed to deliver the BAP1 gene to target cells for research or therapeutic purposes. Adenoviruses are commonly used in gene therapy due to their high transduction efficiency, broad tropism, and ability to infect both dividing and non-dividing cells. The BAP1 adenovirus is designed to restore the functional expression of BAP1 in cells with gene mutations or deletions, thereby reactivating its tumor suppressor function. Preclinical studies have shown that the BAP1 adenovirus has the potential to inhibit tumor growth, promote cell apoptosis, and enhance the sensitivity of BAP1-deficient cancers to chemotherapy or radiotherapy. In addition, this vector is also a valuable tool for studying the molecular mechanisms of BAP1 in vitro and in vivo.